As the global COVID-19 pandemic has continued to develop, it has become apparent that people at the highest risk for complications are those who were already experiencing chronic conditions such as diabetes, chronic obstructive pulmonary disease (COPD), asthma and heart disease. By John Pagliuca & Prasad Dindigal

From the beginning of the COVID-19 pandemic, it has felt like the health care industry has been playing catch-up. Given the fact that the virus and its impact were unknown, clinical leaders and others had to learn about its nature and underlying factors on the fly as they were attempting to treat this devastating pandemic. By Dr. Victor Collymore & Dave Hom

One of the keys to mitigating the effects and stopping the spread of a devastating disease such as COVID-19 is understanding which populations are most vulnerable and at-risk from exposure. By Dr. Victor Collymore

The insurance industry is experiencing seismic shifts in day-to-day operations stemming from this invisible yet intensely disruptive contagion Covid-19… By UK Insurance team

As a result of digitalisation, insurers are compelled to think radically about the way they assess risks, innovate products, manage claims, and, most importantly, manage customer expectations… By UK Insurance team

EXL’s client, a major insurance company faced challenges from the various discontinued products it kept on its books… By UK Insurance Team

COVID-19 makes it difficult to predict what insurers can expect from the future. But we can look back at other crises and gain some meaningful insight into how claims organizations… By Chris Tidball

The ongoing Covid-19 pandemic has put operational resilience firmly on the board level agenda of insurance companies. Resilience is also on regulators’ agenda… By UK Insurance team

For insurance leaders, the full impact of the Covid-19 pandemic will unfold over the coming months, but the rapid evolution of the crisis is forcing organisations to constantly evaluate how they are responding today… By UK Insurance team

For the past two months, the world outside of this industry has been laser-focused on its attempts to speed its way to COVID-19 vaccines and treatments. Dozens of biopharma firms large and small that have turned their development programs on their ears, reallocating huge resources to explore their molecules’ potential in the war on this pandemic. By Susan Willman